Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
But the researchers cannot prove semaglutide caused the eye condition, which can lead to loss of vision in one eye, nor can they explain the increased risk or the difference between the groups
To view or add a comment, sign in Once-Weekly Semaglutide 7.2 mg Shows Superior Weight Reduction in Obesity: Results from the STEP UP Trial Today, results from the STEP UP phase 3b trial were published in The Lancet Diabetes & Endocrinology, evaluating a higher dose of once-weekly subcutaneous semaglutide (7.2 mg) in adults with obesity but without diabetes
Some scientists are concerned about the rates of vision loss among patients who take Zepbound and other GLP-1s
This creates a dilemma
US$ 24.07
US$ 27.13
US$ 21.16
US$ 23.38
US$ 29.79
US$ 23.97
US$ 27.49
US$ 20.84
US$ 22.62
US$ 29.86
US$ 29.90
US$ 27.04
US$ 24.81
